Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TNKS | O95271 | 3/20 | 1.00 |
| ▸ | PARP1 | P09874 | 3/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.80 |
| ▸ | MAOA | P21397 | 2/20 | 0.80 |
| ▸ | MAOB | P27338 | 2/20 | 0.80 |
| ▸ | CA12 | O43570 | 1/20 | 0.80 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.80 |
| ▸ | CA1 | P00915 | 1/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.80 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675776 | 1.00 | CYP3A4 (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| 7-Hydroxyflavone SCHEMBL312148 | 0.89 | CYP19A1 (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| 7-Hydroxyflavone SCHEMBL29678183 | 0.89 | CYP19A1 (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| SCHEMBL4277649 | 0.88 | MAPT (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| SCHEMBL29384142 | 0.88 | TNKS (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| 7-Hydroxyflavone SCHEMBL10808394 | 0.88 | CYP19A1 (0.97) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| 7-Hydroxyflavone SCHEMBL27789687 | 0.88 | CYP19A1 (0.97) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| SCHEMBL29677954 | 0.88 | TNKS (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| SCHEMBL311580 | 0.88 | TNKS (1.00) | CYP3A4HPGDALDH1A1TNKSPARP1 | |
| SCHEMBL12829685 | 0.87 | CYP3A4 (0.79) | CYP3A4HPGDALDH1A1TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | claimed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | claimed |
| CN-119604294-A | ERbeta estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038970-A1 | MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4475837-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| CN-118973616-A | Trkb ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2024026037-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2023154896-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250263774-A1 | DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD | UNIV NORTH TEXAS (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119604294-A | ERbeta estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4475837-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118973616-A | Trkb ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-3328898-B1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | OTONOMY INC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024026037-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023154896-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154896-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11185527-B2 | Methods and compositions relating to steroid hormone receptor-dependent cancers | WAYNE STATE UNIVERSITY (US) | 2021-11-30 | — | — | US | disclosed |
| US-11013717-B1 | Methods and compositions for treating cancer using SERCA pump inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200190201-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | OTONOMY, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200155501-A1 | METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT CANCERS | WAYNE STATE UNIVERSITY (US) | 2020-05-21 | — | — | US | disclosed |
| US-10398760-B2 | Method of treating pain using agents that promote neuronal differentiation | RUSANESCU GABRIEL (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3478269-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | Otonomy, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| CN-109689027-A | Triglycerides aural preparations and application thereof | 奥德纳米有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-108699160-A | TrkB or TrkC agonist compositions and methods for treating otic conditions | 奥德纳米有限公司 | 2018-10-23 | — | — | CN | disclosed |
| EP-3328898-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | Otonomy, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180000897-A1 | Method of treating pain using agents that promote neuronal differentiation | RUSANESCU GABRIEL (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2018005830-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-2730431-B1 | Rubber composition and tire with rubber containing flavone | GOODYEAR TIRE & RUBBER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170029511-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | OTONOMY, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2017019907-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | OTONOMY, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140135433-A1 | TIRE WITH RUBBER CONTAINING FLAVONE | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2730431-A1 | Rubber composition and tire with rubber containing flavone | The Goodyear Tire & Rubber Company (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20100092578-A1 | PROTEIN KINASE C IOTA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| US-7642400-B2 | Transgenic animals, inhibitors of PKC iota signaling, methods for inhibiting PKC iota signaling, identifying inhibitors of PKC iota signaling, and methods for diagnosing cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009026657-A1 | FLAVONOID PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070283451-A1 | Protein Kinase C Iota | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185527-B2 | Methods and compositions relating to steroid hormone receptor-dependent cancers | ESRRA, ESRRB, NR3C1 | CYP3A4 4111/4885HPGD 2535/4885ALDH1A1 3338/4885 |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP3A4 17/4885HPGD 1949/4885ALDH1A1 2000/4885 |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | CYP3A4 4231/4885HPGD 1152/4885ALDH1A1 1277/4885 |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | CYP3A4 1228/4885HPGD 1465/4885ALDH1A1 1116/4885 |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR2, ESR1, ESRRB | CYP3A4 210/4885HPGD 922/4885ALDH1A1 3391/4885 |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | CYP3A4 1323/4885HPGD 1862/4885ALDH1A1 1274/4885 |
| US-20200190201-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | NTRK2, NTRK1, NTRK3 | CYP3A4 4825/4885HPGD 3543/4885ALDH1A1 2996/4885 |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | NTRK2, NTRK1, BDNF | CYP3A4 4808/4885HPGD 3368/4885ALDH1A1 1653/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | CYP3A4 4231/4885HPGD 1152/4885ALDH1A1 1277/4885 |
| US-20170029511-A1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | NTRK2, NTRK1, NTRK3 | CYP3A4 4825/4885HPGD 3543/4885ALDH1A1 2996/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | CYP3A4 3010/4885HPGD 558/4885ALDH1A1 2440/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | CYP3A4 4231/4885HPGD 1152/4885ALDH1A1 1277/4885 |
| US-20200155501-A1 | METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT CANCERS | ESRRA, ESRRB, NR3C1 | CYP3A4 4448/4885HPGD 2740/4885ALDH1A1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.